Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HiSCO16 / PANDORA-G pancrelipase study after gastrectomy during adjuvant chemotherapy
jRCT1061250077Recruiting
- Sponsor
- Hiroshima University Operating Grant, Hiroshima Surgical study group of Clinical Oncology; HiSCO
- Start
- May 2026
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of Pancreaze in gastric cancer (GC) and esophagogastric junction cancer, sponsored by Hiroshima University Operating Grant, Hiroshima Surgical study group of Clinical Oncology; HiSCO. Primary endpoint: Weight loss at 3 and 6 months postoperatively in patients who did not take oral nutritional supplements. Started May 2026; status: recruiting.
02
Drugs
Pancreaze
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on jRCT1061250077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061250077.